The collaboration between Aravind Asokan, researcher at the Gene Therapy Center, and Charles Gersbach, a Duke biomedical engineer, to develop gene therapy for Duchenne Muscular Dystrophy – a rapidly worsening form of muscular dystrophy – is March 6.
Dr. Asokan’s expertise is in gene delivery. Dr. Gersbach’s background is in genome editing. Together they hope to modify DNA sequences to correct disease-causing mutations.